This RSA section is an unofficial mirror, is not legal advice, and may be incomplete, outdated, or incorrectly processed.
RSA 329:1-h · Administration of Epinephrine
329:1-h Administration of Epinephrine. –
Copy link"Administer" means the direct application of epinephrine to the body of an individual.
Copy link"Authorized entity" means any entity or organization in which allergens capable of causing anaphylaxis may be present, including recreation camps and day care facilities. Authorized entity shall not include an elementary or secondary school or a postsecondary educational institution eligible to establish policies and guidelines for the emergency administration of epinephrine under RSA 200-N.
Copy link"Health care practitioner" means a person who is lawfully entitled to prescribe, administer, dispense, or distribute controlled drugs.
Copy linkA health care practitioner may prescribe epinephrine in the name of an authorized entity for use in accordance with this section, and pharmacists and health care practitioners may dispense epinephrine pursuant to a prescription issued in the name of an authorized entity.
Copy linkAn authorized entity may acquire and maintain a supply of epinephrine pursuant to a prescription issued in accordance with this section. Such epinephrine shall be stored in a location readily accessible in an emergency and in accordance with the instructions for use, and any additional requirements that may be established by the board of medicine. An authorized entity shall designate employees or agents who have completed the training required by paragraph V to be responsible for the storage, maintenance, control, and general oversight of epinephrine acquired by the authorized entity.
Copy linkAn employee or agent of an authorized entity, or other individual, who has completed the training required by paragraph V may use epinephrine pursuant to this section to:
Copy linkProvide epinephrine to any individual who the employee agent or other individual believes in good faith is experiencing anaphylaxis, or the parent, guardian, or caregiver of such individual, for immediate administration, regardless of whether the individual has a prescription for epinephrine or has previously been diagnosed with an allergy.
Copy linkAdminister epinephrine to any individual who the employee, agent, or other individual believes in good faith is experiencing anaphylaxis, regardless of whether the individual has a prescription for epinephrine or has previously been diagnosed with an allergy.
Copy link(a) An employee, agent, or other individual described in paragraph IV shall complete an anaphylaxis training program at least every 2 years, following completion of the initial anaphylaxis training program. Such training shall be conducted by a nationally-recognized organization experienced in training unlicensed persons in emergency health care treatment or an entity or individual approved by the board of medicine. Training may be conducted online or in person and, at a minimum, shall cover:
Copy linkHow to recognize signs and symptoms of severe allergic reactions, including anaphylaxis;
Copy linkThe entity or individual that conducts the training shall issue a certificate, on a form developed or approved by the board of medicine to each person who successfully completes the anaphylaxis training program.
Copy linkNo authorized entity that possesses and makes available epinephrine and its employees, agents, and other individuals, or health care practitioner that prescribes or dispenses epinephrine to an authorized entity, or pharmacist or health care practitioner that dispenses epinephrine to an authorized entity, or individual or entity that conducts the training described in paragraph V, shall be liable for any injuries or related damages that result from any act or omission pursuant to this section, unless such injury or damage is the result of willful or wanton misconduct. The administration of epinephrine in accordance with this section shall not be considered to be the practice of medicine or any other profession that otherwise requires licensure. This section shall not be construed to eliminate, limit, or reduce any other immunity or defense that may be available under state law. An entity located in this state shall not be liable for any injuries or related damages that result from the provision or administration of epinephrine outside of this state if the entity would not have been liable for such injuries or related damages had the provision or administration occurred within this state, or is not liable for such injuries or related damages under the law of the state in which such provision or administration occurred. Source. 2021, 122:63, eff. July 9, 2021. 2025, 204:8, eff. July 1, 2025. Examining Board
Copy linkSource note
Source. 2021, 122:63, eff. July 9, 2021. 2025, 204:8, eff. July 1, 2025. Examining Board
Source history
- 2021, 122:63, eff. July 9, 2021
- 2025, 204:8, eff. July 1, 2025. Examining Board
Related materials
Bill relationships
-
2026 HB1292
reference · effective 2027-01-01
withstanding any provision of law to the contrary, the board of medicine shall not revoke, fail to renew, or take any other action against a physician's license issued pursuant to RSA 329 based primarily on a physician's recommendation to [an eligible] a patient regarding or prescription for or treatment with [an investigational] a drug, biologic, or device pursuant to this chapter. II. Notwithstandi
-
2026 HB1292-FN
reference · effective 2027-01-01
withstanding any provision of law to the contrary, the board of medicine shall not revoke, fail to renew, or take any other action against a physician's license issued pursuant to RSA 329 based primarily on a physician's recommendation to [an eligible] a patient regarding or prescription for or treatment with [an investigational] a drug, biologic, or device pursuant to this chapter. II. Notwithstandi
-
2026 HB1321
amend
ravenous therapy. Be it Enacted by the Senate and House of Representatives in General Court convened: 1 New Subdivision; Provision of Elective Intravenous Therapy. Amend RSA 329 by inserting after section 53 the following new subdivision: Provision of Elective Intravenous Therapy 329:54 Definitions. As used in this subdivision, "elective intravenous therapy" means a procedure: I. To admin
-
2026 HB1335
amend · effective 2027-01-01
use of Representatives in General Court convened: 1 New Subdivision; Physicians and Surgeons; Disclosure of Preferential Promotion Received by Provider; When Required. Amend RSA 329 by inserting after section 53 the following new subdivision: Disclosure of Preferential Promotion 329:54 Definitions. In this subdivision: (a) “Preferential promotion” means any financial arrangement, incentiv
-
2026 HB1702
amend
seeking chemical abortions that it may be possible to undo the effects of mifepristone, a drug commonly used to induce abortions. 2 New Subdivision; Chemical Abortion. Amend RSA 329 by inserting after section 53 the following new subdivision: Chemical Abortion 329:54 Definitions. In this subdivision: I. "Chemical abortion" or "medical abortion" means the use or prescription of any drug or
-
2026 HB1702-FN
amend
seeking chemical abortions that it may be possible to undo the effects of mifepristone, a drug commonly used to induce abortions. 2 New Subdivision; Chemical Abortion. Amend RSA 329 by inserting after section 53 the following new subdivision: Chemical Abortion 329:54 Definitions. In this subdivision: I. "Chemical abortion" or "medical abortion" means the use or prescription of any drug or
-
2026 HB1735
reference
withstanding any provision of law to the contrary, the board of medicine shall not revoke, fail to renew, or take any other action against a physician's license issued pursuant to RSA 329 based primarily on a physician's recommendation to [an eligible] a patient regarding or prescription for or treatment with [an investigational] a drug, biologic, or device pursuant to this chapter. II. Notwithstandi
-
2026 HB1735-FN
reference
withstanding any provision of law to the contrary, the board of medicine shall not revoke, fail to renew, or take any other action against a physician's license issued pursuant to RSA 329 based primarily on a physician's recommendation to [an eligible] a patient regarding or prescription for or treatment with [an investigational] a drug, biologic, or device pursuant to this chapter. II. Notwithstandi
-
2026 HB1769
amend · effective 2027-01-01
d medical facilities. Be it Enacted by the Senate and House of Representatives in General Court convened: 1 New Subdivision; Public Funding and Abortion Referrals. Amend RSA 329 by inserting after section 50 the following new subdivision: Public Funding and Abortion Referrals 329:50-a Definitions. I. "Abortion" shall have the same meaning as provided in RSA 132:32, I. II. "Medical fa
-
2026 HB1769-FN
amend · effective 2027-01-01
d medical facilities. Be it Enacted by the Senate and House of Representatives in General Court convened: 1 New Subdivision; Public Funding and Abortion Referrals. Amend RSA 329 by inserting after section 50 the following new subdivision: Public Funding and Abortion Referrals 329:50-a Definitions. I. "Abortion" shall have the same meaning as provided in RSA 132:32, I. II. "Medical fa
-
2026 HB1772
amend
and House of Representatives in General Court convened: 1 New Section; Ibogaine; Administered Under FDA-approved Research Protocol. Amend RSA 329 by inserting after section RSA 329:1-h the following new section: 329:1-i Ibogaine; Administered Under FDA-approved Research Protocol. To the extent allowable by federal law, licensed physicians or qualified licensed practitioners may administer ibogaine
-
2026 HB1772
amend
ct. Be it Enacted by the Senate and House of Representatives in General Court convened: 1 New Section; Ibogaine; Administered Under FDA-approved Research Protocol. Amend RSA 329 by inserting after section RSA 329:1-h the following new section: 329:1-i Ibogaine; Administered Under FDA-approved Research Protocol. To the extent allowable by federal law, licensed physicians or qualified licensed